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Abstract
High-grade gliomas (World Health Organization grade III anaplastic astrocytoma and grade IV glioblastoma multiforme), the
most prevalent primary malignant brain tumors, display a cellular hierarchy with self-renewing, tumorigenic cancer stem
cells (CSCs) at the apex. While the CSC hypothesis has been an attractive model to describe many aspects of tumor
behavior, it remains controversial due to unresolved issues including the use of ex vivo analyses with differential growth
conditions. A CSC population has been confirmed in malignant gliomas by preferential tumor formation from cells directly
isolated from patient biopsy specimens. However, direct comparison of multiple tumor cell populations with analysis of the
resulting phenotypes of each population within a representative tumor environment has not been clearly described. To
directly test the relative tumorigenic potential of CSCs and non-stem tumor cells in the same microenvironment, we
interrogated matched tumor populations purified from a primary human tumor transplanted into a xenograft mouse model
and monitored competitive in vivo tumor growth studies using serial in vivo intravital microscopy. While CSCs were a small
minority of the initial transplanted cancer cell population, the CSCs, not the non-stem tumor cells, drove tumor formation
and yielded tumors displaying a cellular hierarchy. In the resulting tumors, a fraction of the initial transplanted CSCs
maintained expression of stem cell and proliferation markers, which were significantly higher compared to the non-stem
tumor cell population and demonstrated that CSCs generated cellular heterogeneity within the tumor. These head-to-head
comparisons between matched CSCs and non-stem tumor cells provide the first functional evidence using live imaging that
in the same microenvironment, CSCs more than non-stem tumor cells are responsible for tumor propagation, confirming
the functional definition of a CSC.
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Introduction
Human tumors commonly display a heterogeneity within their
neoplastic compartment that may be derived from a combination
of stochastic genetic copy number alterations and an epigenetic
hierarchy that co-evolve over time [1]. Integrating the concept
that tumors may contain a stem cell-like population responsible for
their maintenance and propagation may be informative for both
the cancer and stem cell fields [2]. The CSC hypothesis may
provide insights into therapeutic resistance and tumor recurrence
and underscore the complexity of cancer. The excitement
surrounding the CSC hypothesis is tempered by controversy with
regard to appropriate experimental model systems to functionally
define CSCs, CSC frequency, and universally informative
immunophenotypes [3]. Normal and neoplastic stem cells are
currently defined by functional assays of self-renewal and
differentiation, with the most accurate assay to date for CSCs
being tumor propagation. Xenotransplantation models have
confirmed the enhanced tumor formation capacity of the CSC-
enriched fractions in a variety of human tumors and have been
used to estimate the frequency of tumor propagating cells [4],
which is quite high for some malignancies [3]. As the niche in
which both normal and neoplastic stem cells reside instructs self-
renewal and maintenance, live animal in vivo imaging techniques
have been applied to some stem cell populations – notably
hematopoietic and leukemic stem cells – to determine growth
patterns in the native microenvironment [5,6,7], but the
application to solid tissues has been limited. Solid tumor CSCs
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populations, which have been informative in determining
differentially regulated pathways but have prevented the direct
analysis of tumor propagation potential between different tumor
cell fractions. To evaluate the potential of CSCs in direct
comparison to non-stem tumor cells in a representative microen-
vironment, we differentially labeled GBM cell fractions derived
from a human tumor and monitored tumor behavior in a
xenotransplantation model over time using intravital microscopy.
Despite small numbers of CSCs at transplantation, tumor
propagation was driven by CSCs and their descendants,
demonstrating the ability for CSCs, but not non-stem tumor cells,
to drive tumor formation and propagate cellular heterogeneity.
Materials and Methods
Transplantation of glioma cells
Human glioma cells were derived with written informed consent
and under approved IRB protocols from Cleveland Clinic
(Protocol 2559) and Duke University (Protocol 7409). Glioma
cells were transiently passaged as xenografts in nude mice under
approved Cleveland Clinic IACUC protocol ARC 8699 and in
vivo imaging was performed under Case Western Reserve
University Protocol 2009-0109). For initial CSC tumor formation
studies, the tumor specimen used (T4302) was a newly diagnosed
grade III anaplastic astrocytoma in a 40 year old male which was
surgically removed at Duke University. At time of removal, the
specimen was characterized to have EGFR polysomy (EGFRvIII
negative), MGMT negative, intact PTEN, and polysomy of
chromosomes 7 and 10. For cell mixing studies (i.e. competition
assay), the tumor specimen used (T4121) was a recurrent
glioblastoma multiforme (GBM) diagnosed in a 26 year old male
which was surgically removed at Duke University. At time of
removal, the specimen was characterized to have amplified EGFR
(but EGFRvIII negative), MGMT positive, PTEN loss, loss of
chromosome 9p21, and polysomy of chromosomes 1p36, 1p32,
and 19q13. For experimental studies, tumor cells were removed
from xenografts and CSCs were enriched based on CD133
expression by flow cytometry (using a CD133/2-APC antibody,
Miltenyi) then functionally assayed for self renewal, multi-lineage
differentiation, stem cell marker expression and tumor propaga-
tion as previously described [8]. Putative CSCs from GBM
specimen T4302 were transduced with a lentivirus to express
green fluorescent protein (GFP). For tumor specimen T4121,
putative CSCs were labeled with yellow fluorescent protein (YFP)
or and non-stem tumor cells were labeled with a cyan fluorescent
protein (CFP, tumor specimen T4121) by lentivirus (Sigma).
Labeled CSCs and non-stem tumor cells (derived from T4121)
were mixed at a 10%:90% [or 1:9] (CSC:non-stem tumor cell)
ratio and transplanted into the cortex of a nude mouse at a depth
of 1.5 - 2 mm. Cranial windows were installed as previously
described [9]. Imaging studies utilized 25,000 transplanted cells.
All surgical procedures were done under an approved Cleveland
Clinic IACUC protocol.
Multiphoton imaging
Intravital microscopy was performed using multiphoton imaging
as previously described [10] using a Leica SP5 imaging system with
a 16W femto-second laser tuned to 840–860 nm and focused
through a 20X water immersion lens (numeric aperture of 1.0).
Prior to imaging, mice were anesthetized and intravenously injected
with high-molecular weight fluorescent dextran (.150 kD) to
highlight vasculature. Images were acquired over a 200 mm range
in 2 mm z-stacks. Maximum intensity projections, representing
200 mm in depth, were uniformly adjusted in Photoshop (Adobe)
prior to display. For three-dimensional reconstructions, data was
imported into Imaris software (BitPlane) for surface rendering and
volume was quantified for each cell population.
Immunostaining and statistical analysis
Frozen sections were cut using a cryostat (Leica) and immuno-
staining was done as previously described [11] with antibodies
against Tra1-85 (R&D Systems, 1:500), Sox 2 (R&D Systems,
1:200), phosphorylated Histone H3 (PH3, Millipore, 1:500), and
CD31 (Dako, 1:200). Nuclei were counterstained with Draq5
(Biostatus limited, 1:5000). Images were acquired using a Leica SP5
confocal microscope as previously described [11]. Analysis of the
entire tumor was done for 3 anatomical depths in 3 representative
mice, totaling ,400,000 cells. Immunophenotyping of the trans-
planted cell populations was confirmed by flow cytometry using
CD133 expression (CD133/2-APC antibody, Miltenyi) of each cell
populationaspreviouslydescribed[8].Immunostainingoneachcell
population in vitro was done using antibodies described above and
quantified based on a minimum of 150 cells from 10 fields.
Statistical significance was calculated using one-way ANOVA.
Automated image analysis
Large field-of-view (FOV) images of tumor cross-sections were
acquired using a Leica DM4000, a 40X objective, a Q-Imaging
CCD, a Prior 8-slide motorized stage, Image-Pro 6.2, and YFP,
CFP, CY5 (DRAQ5 labeled nuclei), and Texas Red (Sox2, Tra-1-
85, or PH3) filter cubes. Large FOV images (,500 MB/channel)
were imported into Image-Pro for analysis using customized
macros. For each cross-section, the Draq5 channel was imported
and spectrally enhanced to equalize the appearance of each
nucleus. Nuclei were then segmented, morphologically ‘‘dilated’’
to extend their boundaries into the cytoplasm, and ‘‘watershed’’
filtered for cell separation. A region of interest (ROI) was drawn
around the bulk tumor and CFP, YFP, and Texas Red channels
were loaded in succession. Each channel was spectrally filtered and
‘‘multiplied’’ by the cell mask described above. Segmentation via
morphometric and intensity profiles specific for each marker/stain
followed by image logic operations provided YFP, CFP, and
antibody positive cell counts. For immunophenotyping of the
transplanted population, the resulting binary nuclear mask was
‘‘multiplied’’ with the corresponding PH3/Sox2 channel. Positiv-
ity was automatically assigned based on mean nuclear intensity of
PH3 or Sox2 above a predefined threshold.
Results
Malignant gliomas are solid cancers for which cellular
hierarchies have been reproducibly defined, permitting the
interrogation of cells that can be prospectively enriched for CSC
characteristics, including self renewal, differentiation potential,
stem cell marker expression, and in vivo tumor propagation. To
address differential in vivo tumor propagation potential, we
utilized models in which we had previously demonstrated the
capacity to functionally enrich or deplete for CSC characteristics
in ex vivo assays using fluorescent cell surface marker labeling
[8,11]. While there is controversy surrounding CD133 as a CSC
marker, many proposed glioma CSC markers (including L1CAM
[12], A2B5 [13], and integrin alpha 6 [11]) overlap with CD133.
We find that CD133 enriches for CSCs in the GBM specimens
used for the study and segregates for tumorsphere formation
efficiency as compared to integrin alpha 6 (data not shown).
Additionally, CD133 fractions efficiently propagate secondary
tumors and CD133 enrichment of CSCs from these tumors has
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tyrosine kinase and nitric oxide synthase isoform [14,15].
CD133 expression was assessed after labeling by flow cytometry
with 11% of YFP cells (CSC derived) and 1% of CFP cells (non-
stem derived) being CD133 positive (data not shown). The viral
labeling procedure did not alter growth properties (data not
shown).
In vivo observation of cancer stem cell growth into a
tumor
To date, the growth of solid tumor CSCs has not been evaluated
at single cell resolution over a temporal time course in vivo. To
observe the potential for tumor propagation by CSCs alone, we
used intravital microscopy in an orthotopic xenotransplantation
mouse model to identify and trace the growth of small numbers of
CSCs into a tumor over time (Fig. 1A). Early in the observation
period when limited amounts of CSCs were present (T4302, days
3 to 13), CSCs were associated with blood vessels in the
perivascular niche (Fig. 1B,C) as described by Gilbertson and
co-workers [16] and grew in proximity with blood vessels
(Fig. 1D,E). Over time (from day 13 to 20), a tumor nodule
rapidly formed and tumor cells were observed to infiltrate the
peripheral regions (blue arrows), a common histological hallmark
of malignant gliomas. The results provide the first tumor growth
Figure 1. Multiphoton microscopy reveals tumor propagation from cancer stem cells. Tumor formation in a xenotransplantation model
was observed from GFP-labeled CSCs over time as shown in experimental design schematic (A). Projection micrographs (B-D) demonstrate tumor
formation over time and three-dimensional reconstructions depicted in micrographs (E, E’) revealed tumor cells were closely associated with blood
vessels (E’, shown with white arrows in D, E) and in peripheral areas (D, E, shown in blue arrows). Fluorescent dextran (shown in red) was injected
into the circulation to illuminate blood vessels prior to imaging. Scale bar represents 50 mm.
doi:10.1371/journal.pone.0024807.g001
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tumorigenic potential of the transplanted CSCs.
Cancer stem cells outgrow non-stem tumor cells in vivo
Numerous studies have demonstrated differential tumor
formation capacity between CSCs and non-stem tumor cells
[8,15,17,18], however a head-to-head comparison between the
two populations in high resolution or in a time dependent manner
has not been performed. This evaluation is critical as a malignant
glioma is made up of multiple cell populations, there is cross-talk
between the populations, and how the cell populations interact is
likely to be informative with regards to tumorigenic processes. To
evaluate the behavior of CSCs and non-stem tumor cells in an
identical microenvironment, we transplanted differentially labeled
human CSCs and non-stem tumor cells derived from the same
parental tumor into the same recipient mouse and monitored in
vivo behavior over time using intravital microscopy (Fig. 2A).
Sequential in vivo assessment of the same host bearing an initial
mixture of CSC (10%, YFP labeled) and non-stem tumor cells
(90%, CFP labeled) demonstrated that CSCs outgrew non-stem
tumor cells, with a 51.9 fold volume increase for the CSCs and a
0.92 fold increase for the non-stem tumor cells (Fig. 2B) and there
was limited intermingled growth among populations (Fig. 2C, D).
Using multiple cell populations from the same tumor, these
imaging results provide the first evidence for differential tumor
formation capacity between CSCs and non-stem tumor cells in
vivo using high resolution sequential imaging.
Resulting tumors contained cancer stem cells and their
descendants
The secondary tumors formed by transplanted CSCs contain
multiple cell populations, however previous studies have largely
Figure 2. Multiphoton microscopy reveals cancer stem cell driven tumor propagation. Fractionated CSCs and non-stem tumor cells were
labeled with different fluorescent proteins and transplanted into mice at a 10% cancer stem cell (YFP) to 90% non-stem tumor cell (CFP) ratio as
shown in experimental design schematic (A). CSCs outgrew non-CSCs in vivo as shown in summary graph (B), which was calculated based on three-
dimensional reconstructions of projection micrographs (B, C). Additionally, tumor populations did not intermingle in vivo (non-stem tumor
population indicated by yellow oval). Fluorescent dextran (shown in purple) was injected into the circulation to illuminate blood vessels prior to
imaging. Scale bar represents 100 mm.
doi:10.1371/journal.pone.0024807.g002
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tumor markers but there has been limited information with
regard to the degree of heterogeneity as well as the contribution
of multiple cell types to the development of heterogeneity. After
the mice developed neurological signs (ranging from 37 to 42
days after transplantation), we used histological examination to
confirm the phenotype of the transplanted cells in the resulting
tumors. To delineate the boundaries of the tumors, tissues were
stained for a human specific antigen, Tra-1-85. We found that
while both YFP positive (CSC derived) and CFP positive (non-
stem derived) were detectable, the overwhelming majority of
tumor cells were derived from CSCs; 94.5 percent of Tra-1-85
positive cells within the tumor were YFP positive (CSC derived)
versus 0.2 percent which were CFP positive (non-stem derived,
Fig. 3A, B).
Association between blood vessels and cancer stem cells
and their descendants
The ability for tumor cells to grow along blood vessels is a
phenotype that is frequently identified in human glioma surgical
specimens. To evaluate if this phenotype was recapitulated in
tumors resulting from co-transplantation of CSCs and matched
non-stem tumor cells, we assessed tumor vasculature using
multiphoton microscopy and histological examination of resulting
tumors (Fig. 3C, D). At day 38 (shown in Fig. 2B), were we able to
identify a group of tumor cells at the periphery of the tumor and
three-dimensional analysis demonstrated that the CSCs and their
descendants (YFP cells) were in close proximity to the vasculature
(Fig. 3C). Histological examination of resulting tumor using an
antibody against CD31 to mark blood vessels also confirmed that
CSCs and their descendants (YFP+ cells) were indeed close to the
Figure 3. Histological evaluation reveals tumors contained cancer stem cells and their descendants that had association with blood
vessels. Tumors from the cell mixing experiments (n=3) were evaluated to determine their composition. Subsequent evaluation of resulting tumors
demonstrates that the majority of the cells within the tumor mass was of human origin and derived from CSC as confirmed by Tra-1-85 staining and
YFP expression, shown in representative micrographs (A) and bar graph (B). Peripheral transplanted tumor cells (YFP positive CSCs and their
descendants) were observed to have an association with blood vessels. Micrograph from multiphoton imaging and three-dimensional reconstruction
(C) depict close association of tumor cells (green) with adjacent blood vessel (purple, illuminated by fluorescent dextran injection into the circulation
prior to imaging). Histological examination of resulting tumors confirms close association of peripheral tumor cells to the vasculature using CD31
immunostaining (D; CD31 in red, tumor cells in green, nuclei in purple). Scale bar represents 50 mm. Data displayed as mean values +/- S.E.M. ***,
p,0.001 as assessed by one-way analysis of variance (ANOVA).
doi:10.1371/journal.pone.0024807.g003
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phenomenon also observed in GBM patients (Fig. 3D).
Cancer stem cells propagate heterogeneity in vivo
To determine if the transplanted tumor cells contained stem-like
cells, we evaluated the expression of the CSC marker, Sox2 [19],
and found that 25.9 percent of transplanted CSCs and their
descendants (YFP cells) were Sox2 positive as compared to 0.1
percent of non-stem tumor cells and their descendants (CFP cells,
Fig. 4A, B). We also assessed proliferation using the M-phase
marker phosphorylated-histone H3 (PH3) and found that 1.7
percent of CSCs and their descendants (YFP cells) were actively in
M-phase as compared with less than 0.01 percent of non-stem
tumor cells and their descendants (CFP cells, Fig. 4C, D). These
differences in proliferation seen in our model support clinical
reports that suggest proliferating CSCs (based on CD133-positive
status) characterize an aggressive class of GBM tumors [20].
To gain an appreciation for the degree of heterogeneity
established by the transplanted CSCs (YFP positive cells), we
evaluated the phenotype of the cells prior to transplantation. The
CSC cultures contained 74.8 percent Sox2 positive cells (i.e. in
vitro) as compared to 24.9 percent of Sox2 positive YFP cells (CSC
derived) within the tumor (i.e. in vivo, Fig. 5A–C). These results
suggest that the in vivo environment provides instructive cues to
recreate an equilibrium of differentiation status and thus cellular
heterogeneity. A similar reduction was seen in Sox2 positive non-
stem tumor cells (CFP cells) from an initial population of 7.1
percent in culture to 0.1 percent in the tumor (Fig. 5A-C).
Differences in growth were also observed between populations in
culture as compared to within the tumor. Using the M-phase
marker PH3 as a surrogate of proliferation, we observed 2.1
percent YFP positive cells (CSC derived) and 0.2 percent CFP
positive cells (non-stem derived) in culture as compared with 1.7
percent YFP positive cells and less than 0.01 percent CFP positive
Figure 4. Tumors contain fractions of stem-like and proliferating cells that originated from cancer stem cells. Histological examination
was performed from resulting tumors in the cell mixing experiments (n=3) to determine the fraction of stem-like cells as assessed by Sox2 expression
and the presence of proliferating cells as confirmed by the M-phase marker phosphorylated histone 3 (PH3). Representative micrographs (A) and bar
graph (B) demonstrate Sox2 expression (red) is associated with cancer stem cells and their descendants (green) but not with non-stem tumor cells
and their descendants (blue). Representative micrographs (C) and bar graph (D) demonstrate PH3 expression (red) is associated with cancer stem
cells and their descendants (green) but not with non-stem tumor cells and their descendants (blue). Scale bar represents 50 mm. Data displayed as
mean values +/2 S.E.M. ***, p,0.001 as assessed by one-way analysis of variance (ANOVA), nuclei counterstained with Draq5 (purple).
doi:10.1371/journal.pone.0024807.g004
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although non-stem tumor cells predominated at early time points
due to the ratios at the time of transplantation, growing tumors
had limited numbers of cells derived from non-stem tumor cells, of
which few expressed stem cell markers or were actively
proliferating. The resulting tumors were comprised of CSCs and
their descendants, a fraction of which still contained stem cell
marker expression and were actively proliferating.
Discussion
The tumor microenvironment is a critical regulator of tumor
formation and maintenance with contributions to therapeutic
response and failure. However, many CSC and brain tumor
studies have not appropriately modeled the microenvironment.
Often CSC and non-stem tumor cells are grown in different
conditions that include different media and CSCs grown as
Figure 5. CSCs and non-stem tumor cells prior to transplantation contain different fractions of stem-like and proliferating cells.
Representative micrographs (A) and bar graph (B) of expanded cells prior to transplantation demonstrate Sox2 and PH3 expression (red) is higher in
the CSC fraction of cells as compared with the non-stem tumor cells. Summary figure depicts marker expression from in vivo and in vitro analyses (C).
Scale bar represents 50 mm. Data displayed as mean values +/2 S.E.M. ***, p,0.001 and N.S. represents not significant (p.0.05) as assessed by one-
way analysis of variance (ANOVA), nuclei counterstained with Hoechst 33342 (blue).
doi:10.1371/journal.pone.0024807.g005
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conditions activate different cell signaling pathways, some CSC
results may be due to culture artifact rather than intrinsic cellular
differences. Many studies are performed with the populations in
isolation, which does not allow for signaling between cells that is
critical for cell growth or the evaluation of each cell type’s
contribution to tumor formation in vivo. Furthermore, niche
interactions with components such as the vasculature or stroma
cannot be fully evaluated unless studies are performed in vivo. To
better model the tumor microenvironment, we differentially
labeled CSCs and non-stem tumor cells and introduced the cells
into the same in vivo conditions. Our evaluation of growth
provides the first direct evidence for tumor propagation by a solid
tumor CSC subpopulation in vivo using live imaging and shows
that a small fraction of tumor cells can propagate a heterogeneous
tumor. Our studies offer substantial advantages over ex vivo or
matched population studies due to our ability to more appropriate
model the in vivo environment and assess the behavior of multiple
populations in real time using high resolution microscopy.
There are many aspects of xenotransplantation models that
provide potential advantages, however there are still limitations.
Conceptually, these transplant assays offer a better in vivo
environment at expense of an appreciation for tumorigenic
processes in real time, which can only be inferred after tumor
formation. However, this black box approach can be addressed
with the use of live imaging as described in this report. Using live
imaging, the intricacies of the xenotransplantation model can be
elucidated and informative predictions can be made for tumor
development, maintenance, and response to therapy. Careful use
of xenotransplantation models will allow for a greater understand-
ing of the interaction between CSCs and non-stem tumor cells, as
well as cellular communication with blood vessels, a CSC niche in
several brain tumors [16]. Additionally, these approaches may
clarify the recently identified phenomenon of GBM CSC
differentiation into vascular cells and clarify the role of this
plasticity in tumorigenic processes [21,22,23,24]. Of note, we did
not observe integration of labeled cells into the vascular wall (data
not shown). These vascular interactions have far reaching
therapeutic implications especially in the context of angiogenesis
where many therapies are under investigation. In addition, a
greater appreciation of the interplay between the microenviron-
ment and transplanted tumor cells may help explain the delay in
tumor growth in transplantation models. This is highlighted by our
observations shown in Figure 1 where CSC growth between day
35 to day 38 is quite remarkable, but congruent with the dynamics
of tumor growth within a transplantation model [25,26]. These
differences are likely to be a reflection of a multi-stage process
which includes tumor cell survival, adaptation to the host
environment, followed by exponential growth, which can be
extrapolated to understand recurrence in patients.
Our data also demonstrate that such an approach can be used to
better define cancer cellular heterogeneity, which will be critical for
both the basic understanding of tumorigenesis and a model to more
appropriately test promising pre-clinical therapies. In our studies,
the resulting tumors that formed contained a heterogeneous
population, as assessed by Sox2 expression, despite the substantial
representation of YFP cells (CSC derived). This type of in vivo
lineage tracing has been limited in GBM studies and our results
confirm that CSCs expressing a stem cell marker can generate cells
that do not express the stem cell marker, demonstrating the
transitionbetweenstemcellstatesinvivo.Pre-clinicalstudiesrelyon
tumor size as an estimation of efficacy. Our demonstration that a
small fraction of cancer cells propagates a tumor in vivo represents a
complementary approach to evaluate the efficacy of a given
treatment by lineage tracing. Taken into a clinical context, a
therapy that kills the majority of cells and leaves behind a small
population of refractory cells (likely to be enriched in CSCs) will
appear effective if tumor size is the measured outcome. However,
theremaining cells,some ofwhich areCSCs,arelikelyto contribute
to tumor recurrence, as often seen in patients after therapies
effective in reducing tumor size [27]. Hence, evaluating cellular
lineages in a tumor after therapy in combination with tumor size
assessments and histological analysis is likely to provide a more
accurate view of the impact of the treatment. The ability to evaluate
tumor cell behavior itself in a relevant clinical model is valuable.
Our data (this report and [11,28]) and those from other groups [16]
indicate that tumor cells have an intimate relationship with the
vasculature; however, the FDA approved vascular endothelial cell
growth factor (VEGF) neutralizing antibody bevacizumab (Avastin)
has had mixed success clinically, despite success in pre-clinical
models [29]. Resistance to anti-VEGF therapies is postulated to
occur through evasion or indifference and involve modulated
angiogenesis, vasculogenesis, vascular normalization [30,31]. How-
ever, the dominant mode of resistance is yet to be determined and
our approach using multiple tumor cell populations and high
resolution in vivo microscopy is likely to provide critical insight. For
greater impact, these methods can be combined with use of
fluorescent reporter systems to evaluate the transcriptional activity
inrealtime and incorrelation to therapeutic response.Another area
in which these imaging approaches will be helpful is the evaluation
of sonic hedgehog (Shh) inhibitors. It is unclear if the mode of action
is directly ontumorcells,thetumorstroma, orboth,andelucidation
of the mechanism of action is an immediate priority as several Shh
inhibitors are currently under investigation for a variety of tumors
including GBM [32,33]. Using the approach described in this
report, the examination of CSCs in a context that closely resembles
the native microenvironment combined with live imaging will help
accelerate our understanding of CSCs and put their associated
changes in response to therapy into a relevant context.
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